Our dedicated team engages with key formulary decision-makers on behalf of patients.
Sandoz is the only company to offer both a liquid pen and a lyophilized-powder vial at different price points, giving more options to payers and patients.1
Omnitrope has 6 indications to serve a wide variety of patients who are prescribed growth hormone.2
OmniSource is here to help give HCPs the support they need to get their patients on therapy quickly and efficiently.
Co-pay support through OmniSource provides a financial benefit to make growth hormone therapy more affordable for your patients.*
Eligible patients may receive their medication and injection device within 10 business days of qualifying for SOS, so they don’t have to delay their treatment while waiting for insurance approvals.
SOS can cover patients for up to 1 full year of interim treatment assistance.†
*Omnitrope Co-Pay Savings Program Eligibility:
The Omnitrope Co-Pay Savings Program provides up to $5000 in annual Co-Pay support for Omnitrope prescriptions. With the Omnitrope Co-Pay Savings Program, eligible patients may pay $0 for their Co-Pay. Eligible patients who are commercially insured may receive Co-Pay support in the amount of up to $5000 annually, and patients who are uninsured may receive Co-Pay support in the amount of up to $417 monthly, with an annual cap of $5000. Prescription must be for an approved indication. This program is not health insurance. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DoD, or TRICARE, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Patients can participate for a maximum of 12 months. Eligible patients must have a first use of the program by December 31 of the current year. Omnitrope Co-Pay Savings Program may not be combined with any other rebate, coupon, or offer. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice. Omnitrope Co-Pay Savings Program has no cash value.
†SOS is available for a maximum of twelve (12) months to commercially insured patients with an FDA-approved Omnitrope indication during first-time benefits investigation and expired prior authorizations. SOS is also available for a maximum of two (2) months to government-insured patients with an FDA-approved Omnitrope indication during first-time benefits investigation only. This program is not health insurance. Product dispensed under SOS is not eligible for claim reimbursement and should not be submitted to any third-party private payer. SOS does not require, nor will be made contingent on, purchase requirements of any kind. Sandoz reserves the right to amend, rescind, or discontinue this program at any time without further notice. Additional eligibility criteria may apply. Contact OmniSource for further details.
Omnitrope® is a recombinant human growth hormone indicated for: